Walgreen (NYSE: WAG), a drugstore business that competes with CVS Caremark (NYSE: CVS) and Rite-Aid (NYSE: RAD), will be issuing results for the third quarter on Monday, June 22. According to Earnings.com, the analyst community is prescribing $0.56 per share for the company.

Of course, the question is: will Walgreen honor that prescription and fill it? I'd say it's quite possible. Last time around, Walgreen beat estimates. The call was for $0.66 per share in Q2. If you look at the press release from that time, you'll see that, once you adjust for some items, Walgreen went beyond expectations.

Walgreen (NYSE: WAG ) knows that people want all kinds of options to meet their healthcare needs. Walgreen also knows that it needs to grow and keep up with competitor CVS Caremark (NYSE: CVS) and the pharmacy department at Wal-Mart (NYSE: WMT). And, yes, I suppose Rite-Aid (NYSE: RAD) is technically a competitor, too, although you wouldn't know it by that drugstore chain's stock price. Well, according to The Wall Street Journal, Walgreen plans to promote an initiative called "Complete Care and Well-Being" to employers. The goal here is to give corporate, as well as government, employees and their families access to healthcare services such as preventive medicine and dental examinations in off-hour time periods. Walgreen will use a network of in-store clinics and health centers to provide these services. That's pretty cool, right? Well, one of the bigger benefits to Walgreen is the synergy it can promote by leveraging this program.

Walgreen (NYSE: WAG), a major drugstore chain whose enemies include CVS Caremark (NYSE: CVS) and Rite-Aid (NYSE: RAD), is getting ready to report earnings for its first fiscal quarter on Monday, December 22. It's Christmas week. Will Walgreen bestow a gift of an earnings beat upon the market?

One thing's for sure: the market does not expect much from the drugstore. Wall Street expects flat performance in Q1. The bottom line should come in somewhere around $0.46 per share, the exact same amount that was booked last year. You know, you figure the company should be able to at least match expectations when the bar is set so low. But it might be tough. We all need access to prescriptions and over-the-counter medications every now and then, and on top of that, many people obviously require long-term drug regimens. So, we can see that the pharmacy part of the equation is somewhat resistant to recession. However, there isn't a pressing need for all the non-pharmacy items in a Walgreen location. You don't need to buy any of those cheap plastic toys, any of those blenders that don't work too well, any of the overpriced groceries, etc. This is where Walgreen has exposure to the weakening consumer. Indeed, the consumer is becoming more and more of a value Grinch as time goes on. People just don't want to pay any more than they have to.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Adobe Systems Inc. (NASDAQ: ADBE) posted strong Q4 and full-year results, but with flat Q4 revenues.
• Best Buy Inc. (NYSE: BBY) beat Q3 expectations though earnings tumbled, and shares rose about 18%.
• Carnival Corp. (NYSE: CCL) announced that it had lowered its full-year earnings and revenue guidance.
• Discover Financial Services (NYSE: DFS) net income from continuing operations more than doubled in Q4.
• Eaton Corp. (NYSE: ETN) cut its Q4 earnings guidance on weakness in the American auto market.
• FedEx Corp. (NYSE: FDX) Q2 earnings topped expectations and it reaffirmed its guidance.
• General Electric Co. (NYSE: GE) declined to provide quarterly earnings guidance in its annual outlook.
• General Mills (NYSE: GIS) posted a higher-than-expected profit on cost cutting and increased marketing.
• Gilead Sciences Inc. (NASDAQ: GILD) strong earnings growth are expected by one analyst to continue.
• Goldman Sachs Group (NYSE: GS) swung to an anticipated Q4 loss and reported negative revenues.
• Healthcare Realty Trust Inc. (NYSE: HR) was downgraded due to its near-term earnings prospects.
• Honeywell International Inc. (NYSE: HON) affirmed a lower 2009 outlook and said it expects profits to fall.

Rite-Aid Corporation (NYSE: RAD) is the drugstore you should avoid. You can consider CVS Caremark (NYSE: CVS). You can take a look at Walgreen Company (NYSE: WAG). Rite-Aid? It's definitely not the cure for an ailing portfolio.

The troubled pharmacy chain is no stranger to losses and its public stock sits well below a buck a share. The third quarter numbers don't look too appealing. On an adjusted basis, Rite-Aid lost $0.15 per share. That may have been better than what analysts were calling for, namely a loss of $0.17 per share, but you have to look at the overall picture. Rite-Aid is closing stores, and that will hamper sales going forward (not to mention its brand equity, as well). Some will argue that it's all part of the turnaround. Sure, turnarounds can be ugly and painful, granted, but that doesn't mean you have to participate, hoping for the best. Why hop on this low-priced equity when integration of the Brooks Eckerd assets doesn't seem to be going very well?

According to the press release, there are a few positive statistics. Management says that overall same-store sales were up 1.4%, EBITDA increased over 8%, and operational cash flow was positive over the last three quarters (by comparison, cash was used for operations in the year-ago similar period). But the guidance isn't good, and I have no confidence in this management team to improve its GAAP performance. The company has to juice its sales, but with competition from stronger foes like CVS Caremark and Walgreen, I just don't see any silver lining to the Rite-Aid story. Turnaround specialists can make whatever argument they want. As for me, I'm going to make like the galaxy in Star Wars and stay far, far away from Rite-Aid's stock...

Disclosure: I don't own any company mentioned; positions can change at any time.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Bed Bath & Beyond Inc. (NASDAQ: BBBY) Q1 earnings tumbled while revenues rose.
• Casella Waste Systems Inc. (NASDAQ: CWST) posted a narrower-than-expected Q4 loss.
• CKE Restaurants Inc. (NYSE: CKR) Q1 earnings increased but its revenue slipped.
• Darden Restaurants Inc. (NYSE: DRI) swung to a Q4 profit on strong sales at Olive Garden.
• Ericsson (NASDAQ: ERIC) said it might not see Q2 profit growth on lower demand and shipping delays.
• General Mills Inc. (NYSE: GIS) Q4 earnings declined but were in line with expectations.
• Gerber Scientific Inc. (NYSE: GRB) reported solid Q4 and full-year results that pleased investors.
• IHS Inc. (NYSE: IHS) beat Q2 expectations and posted record quarterly cash flow from operations.
• Jabil Circuit Inc. (NYSE: JBL) stronger-than-expected Q3 results led to an analyst's upgrade.
• KB Home (NYSE: KBH) widened its Q2 loss due to weak sales and falling prices.
• Kroger Co. (NYSE: KR) beat Q1 expectations as consumers sought discounts on food and gas.
• Monsanto Co. (NYSE: MON) beat Q3 earnings estimates but fell short of revenue estimates.
• Nike Inc. (NYSE: NKE) posted better-than-expected Q4 results boosted by international strength.
• Oracle Corp. (NASDAQ: ORCL) posted strong Q4 results that topped analysts' expectations (see transcript).

Rite-Aid (NYSE: RAD), a competitor of CVS (NYSE: CVS) and Walgreen (NYSE: WAG), tanked Thursday. By the end of the trading session, the pharmacy's stock declined almost 23% on heavy volume. Yes, it was a horrible day in the market overall, but don't blame the market at large. Rite-Aid is simply a company to avoid, and its latest earnings data show why.

According to the AP, Rite-Aid booked a loss of $0.20 per share for its fiscal first quarter versus a profit of $0.04 per share in the year-ago period. There are some growing pains going on here, since Rite-Aid is attempting to integrate its purchase of Brooks Eckerd. That acquisition propelled the company to top-line revenue growth of 48%. Unfortunately, analysts were looking for the company to lose only $0.09 per share. The significant differential made investors feel justified in punishing the stock. Heck, I'll bless the sell-off myself.

It'll be a long time before Rite-Aid finally turns its ship around. The next fiscal year will bring more losses, and with strong competition out there from CVS and Walgreen, the road ahead for management won't be for the faint of heart. This is truly a speculator's stock. I took a look at a post I wrote on Rite-Aid back near the beginning of April. At that time, the stock was priced at about $2.89 per share. As of Thursday's close, the shares were trading for $1.35. The Rite-Aid story belongs in the horror genre, and its stock is best left to those professionals who don't mind losing money. Individual investors? This company isn't for you, in my opinion.

Disclosure: I don't own any company mentioned; positions can change at any time.

Walgreen (NYSE: WAG) reported sluggish Q3 numbers last week. Net sales increased a little under 10% to $15 billion. Net income increased a whopping two pennies to 58 cents per diluted share (the term "whopping" is used here sarcastically). According to this article, Walgreen met top-line expectations but missed the bottom-line call by a penny.

Gross margin remained relatively stable, but the net margin dropped to 3.8% in the quarter compared to 4.1% in the previous year's similar period. But same-store sales increased 3.4%, which is a decent number. Also, operational cash flow jumped over 19% to $2.5 billion. That's excellent; it's always good to see cash coming in. It helps mitigate the tepid earnings expansion. Walgreen did well with its cash-flow statement last time around as well. Walgreen management cited the economy as a factor in its earnings stats and highlighted the fact that it cut back on expenses, including advertising. Making sure costs don't get out of hand is important, but I'd be careful about eliminating too much of the advertising budget. Competing with CVS Caremark (NYSE: CVS), Rite-Aid (NYSE: RAD), and the pharmacy at Wal-Mart (NYSE: WMT) obligates brand-building and differentiation.

Walgreen's Q3 wasn't beyond awesome, but it was solid enough. The stock is only down slightly as I write this. As a long-term play on the need for drugstores, it's not a bad way to go.

Disclosure: I don't own any company mentioned; positions can change at any time.

The inner city of my midwestern home town has long been plastered with ads for paternity testing services, which I see as a sad commentary on our society. Today's New York Times reports that this service has become even easier, via an at-home test kit now for sale in Rite Aid (NYSE:RAD) drug stores in the Northwest.

The Identigene kit from Sorenson Genomics retails for $29.99. It contains three cotton swabs- one each for child, mother and father-candidate. After each has wiped a swab against his/her inner cheek (or DNA-containing material is otherwise collected), they are mailed to the Sorenson labs. Results are returned within about five days.

The company does not represent this test as admissable evidence for legal purposes, but will set up the proper chain of evidence for an additional $200. Sorenson told the NYT it already sells over 1,500 kits per month via the internet, and expects this new venue to drive more traffic.

I wonder if this might be enough to convince young and carefree serial fathers to finally take responsibility for their actions by adopting condom use. Obviously, morals and concern for their own health have not. Maybe their wallet is their soft spot.

With Wal-Mart Stores Inc. (NYSE: WMT) and Target Corp (NYSE: TGT) set to challenge the traditional drug store chains as they lower prices on prescription generic drug, what is in store for national chains like CVS Corp (NYSE: CVS) and Walgreens? You'd never know that CVS feels threatened, yet, especially after the retailer reported rising sales for the September same-store sales period.

No surprise, since the full effect of Wal-Mart's massive move, which is only available in Florida for now, has not yet shaken up the retail drug industry. Add Target into that mix, and by this time next year, the heat may indeed be on, having a large impact on CVS and Rite-Aid among other. Rite-Aid is also in the midst of buying national drug retailer Brooks Drugstores from Canada's Jean Coutu.

CVS increased its third-quarter EPS guidance range to 31 to 33 cents from a previous range of 28 to 30 cents -- but a few more quarters of upped guidance may be all that's left in store for CVS and other retailers as they start feeling the heat of Wal-Mart and Target. Will they match the new 40% discounts on over 300 generic prescription drugs in an attempt to keep customers? If not, what do you think -- will Rite-Aid, CVS and Walgreens have a rosy or dark 2007?

Eckerd and Brooks Drugstores, which were purchased by Canada's Jean Coutu Group just a few years ago, are being brought back under American ownership, as the Rite-Aid chain has agreed to purchase both companies back from Jean Coutu for $2.55 billion (excluding debt). The goal is to make Rite-Aid the largest drugstore chain on the U.S. East Coast.

The move will put Rite-Aid on the level of drug retailing giants Walgreen's and CVS Drugstores. CVS, actually, ended up purchasing about half of the former Eckerd chain back in the 2004 sale, with half the Eckerd Stores going to CVS and half to Jean Coutu. Many Eckerd drugstores were then re-branded CVS all over the nation where the Eckerd stores that weren't sold to Jean Coutu were located.

It's kind of ironic that the Eckerd brand is being re-purchased again and will probably be re-branded Rite-Aid once the acquisition is complete and the sale is final. Jean Coutu will gain a 32% stake in the new Rite-Aid under terms of the deal, and Rite-Aid's acquisition will include 1,858 drugstores -- including 337 Brooks stores, 1,521 Eckerd stores and six distribution centers. All these locations are primarily on the East Coast and in the Mid-Atlantic states.

Brian White has worked in various executive positions in technology and telecommunications and now focuses on editing and writing.